Clinical Trials Browser

INDUSTRY × Neoplasms × Tumor-Agnostic × Clear all

NCT04606381 2026-06-05

PALOMA

Phase 1 Active not recruiting

Neoplasms

NCT06178614 2026-06-05

A Study of JNJ-87890387 for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT06311578 2026-06-05

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT06901531 2026-06-05

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT07005102 2026-06-05

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Neoplasms

NCT07525141 2026-06-05

A Study of JNJ-1761981 in Participants With Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT07630974 2026-06-05

MK-9999-01D

Phase 1/2 Not yet recruiting

Neoplasms

NCT06761976 2026-06-04

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Neoplasms

NCT03899155 2026-06-03

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT07247110 2026-06-03

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Phase 1 Recruiting

Neoplasms

NCT03435796 2026-06-02

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Phase 2/3 Recruiting

Neoplasms

NCT06183151 2026-06-01

CaVe

Neoplasms

NCT00463814 2026-05-29

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Phase 1 Active not recruiting

Neoplasms

NCT04145622 2026-05-29

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT04401020 2026-05-29

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Phase 1 Completed

Neoplasms

NCT06593522 2026-05-28

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Phase 2 Active not recruiting

Neoplasms

NCT07612176 2026-05-28

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Phase 1 Recruiting

Neoplasm Metastasis, Neoplasms

NCT07612488 2026-05-28

A Study of CS231295 in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

Neoplasms

NCT04958239 2026-05-27

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1 Active not recruiting

Neoplasms

NCT07438782 2026-05-27

First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT07209111 2026-05-26

KANDLELIT-014

Phase 2 Recruiting

Neoplasms

NCT05673018 2026-05-22

Galleri® in the Medicare Population.

Phase NA Recruiting

50,000 enrolled

Neoplasms

NCT06431594 2026-05-22

BEHOLD-1

Phase 1 Recruiting

Neoplasms

NCT06551142 2026-05-22

PanTumor-101

Phase 1 Recruiting

Neoplasms

NCT06589310 2026-05-22

Falcon Real World Evidence Registry

25,000 enrolled

Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT07600749 2026-05-22

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

Phase 1 Not yet recruiting

Neoplasms

NCT04130542 2026-05-19

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Phase 1 Completed

Neoplasms

NCT04635995 2026-05-19

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Phase 1 Completed

Neoplasms

NCT05303532 2026-05-19

ROSY-D

Phase 3 Enrolling by invitation

Neoplasms

NCT06883058 2026-05-18

CASA

Phase NA Enrolling by invitation

Neoplasms

NCT05155605 2026-05-14

PATHFINDER 2: A Multi-Cancer Early Detection Study

Phase NA Active not recruiting

35,883 enrolled

Neoplasms

NCT06979596 2026-05-13

OMAHA-015

Phase 2 Recruiting

Neoplasms

NCT05862285 2026-05-12

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT06150157 2026-05-12

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Phase 1 Recruiting

Neoplasms

NCT06941272 2026-05-12

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT05076396 2026-05-11

PM14 Administered Intravenously to Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02354547 2026-05-08

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

Phase 1 Suspended

Neoplasms

NCT02908906 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT05376891 2026-05-08

Met Non Small Cell Cancer Registry (MOMENT)

Neoplasms

NCT06818643 2026-05-08

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase 1/2 Recruiting

Neoplasms

NCT06046066 2026-05-07

A Phase 1 Study of NM6603 in Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT06555744 2026-05-07

A Study of ZW191 in Participants With Solid Tumors

Phase 1 Active not recruiting

Neoplasms

NCT05572970 2026-05-06

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Neoplasms

NCT03872778 2026-04-30

NeoRay

Phase 1/2 Completed

Neoplasms

NCT05378425 2026-04-30

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Phase 1 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT06010342 2026-04-28

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

Phase 2 Recruiting

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT04452955 2026-04-22

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Phase 2 Active not recruiting

Neoplasms